The Chinese folks i know were talking to my partner & told her + sent the following & then she translated it back to English for me so there are a few errors. Part of this translation includes a report from Frost & Sullivian. when searching for it, it looked like it was from a article about 6 months ago but a lot of the below is missing. Anyway they/chinese friends have ran for the Hills after buying from around 15rmb up to the mid twentys then watched it run to 30 rmb & then back down to a new 52 week low a couple days or so ago. They just acted on this information so i believe some of it is new or being that its China, maybe they just starting recieveing a lot of it?? Anyway here is what they sent, not sure if this is somehow effecting RVX from moving forward?? 

"The title of the article is: the IPO of the former king of stocks in Hong Kong, embarrassing performance is suspected of water, Li Li, the former richest man can realize his dream in...

Expose financial, internal control and other problems
According to Frost and Sullivan, Hepalink is the largest manufacturer and distributor of enoxaparin sodium injection in China and the fourth largest in the world in terms of global sales in 2018, accounting for 5.4% of the global market share. In recent years, Hepaloft has focused on overseas markets and has global business in the pharmaceutical field, innovative biotechnology field and CDMO field. It's Enoheparin Sodium Injection brand has been approved and sold in 15 countries worldwide in 36 countries

Expose financial, internal control and other problems
According to Frost and Sullivan, Hepalink is the largest manufacturer and distributor of enoxaparin sodium injection in China and the fourth largest in the world in terms of global sales in 2018, accounting for 5.4% of the global market share. In recent years, Hepalink has focused on overseas markets and has global business in the pharmaceutical field, innovative biotechnology field and CDMO field. It's Enoheparin Sodium Injection brand has been approved and sold in 15 countries worldwide in 36 countries Expose financial, internal control and other problems
According to Frost and Sullivan, Hepalink is the largest manufacturer and distributor of enoxaparin sodium injection in China and the fourth largest in the world in terms of global sales in 2018, accounting for 5.4% of the global market share. In recent years, Hepalink has focused on overseas markets and has global business in the pharmaceutical field, innovative biotechnology field and CDMO field. It's Enoheparin Sodium Injection brand has been approved and sold in 15 countries worldwide in 36 countries In order to further consolidate its market share, Hyper filed its prospectus with the Hong Kong Stock Exchange on January 23, 2020, marking the ten-year mark of A-share listing. However, standing in the spotlight of "A+H", Hepalink has been frequently exposed problems in finance, internal control and other aspects, which have attracted wide attention in the industry.
In December 2019, Hepalink received 5 letters of decision on regulatory measures from Shenzhen Securities Regulatory Bureau. According to the written decision on regulatory measures, after the inspection by Shenzhen Securities Regulatory Bureau, there are three problems of "non-standard accounting related to equity investment of overseas companies", "insufficient internal control over the pricing of related transactions and relevant information disclosure", and "insufficient registration and management of insiders of inside information of some major matters"In order to further consolidate its market share, Hyper filed its prospectus with the Hong Kong Stock Exchange on January 23, 2020, marking the ten-year mark of A-share listing. However, standing in the spotlight of "A+H", Hepalink has been frequently exposed to problems in finance, internal control and other aspects, which have attracted wide attention in the industry.
In December 2019, Hepalec received 5 letters of decision on regulatory measures from Shenzhen Securities Regulatory Bureau. According to the written decision on regulatory measures, after the inspection by Shenzhen Securities Regulatory Bureau, there are three problems of "non-standard accounting related to equity investment of overseas companies", "insufficient internal control over the pricing of related transactions and relevant information disclosure", and "insufficient registration and management of insiders of inside information of some major matters"